How Technology Partner Programs Drive CRO Competitive Advantage—and Patient Impact
In this episode of the Driving the Business of Science podcast, host Keith Parent, CEO of Court Square Group, interviews Mitchell Bayer, Managing Principal of Arlen Consulting Group, about the evolution of the life science industry and the role of CROs. Mitch discusses his 24-year career, starting at Medidata, where he spearheaded the ASPire to Win™ CRO partner program, which grew to 16 partners by 2009. He emphasizes the importance of integrating technology with CROs to enhance competitiveness and efficiency. Mitch highlights the shift from paper-based trials to electronic data capture (EDC) and the potential of AI in streamlining clinical trials. He also discusses the importance of technology that integrates seamlessly with existing systems and reduces site burden.
Listen on your favorite podcast platforms
iHeart Radio | Apple Podcasts | Spotify | Amazon Music | Buzzsprout
Guest Profile – Mitchell Bayer, Managing Principal, Arlen Consulting Group
With over 24 years of experience in clinical trial technology, Mitch began his life sciences career at Medidata Solutions, as the company’s 12th employee (2002–2016). In 2005, he spearheaded the commercialization of ASPire to Win, Medidata’s and the industry’s first formal, enablement-based partner program between a Contract Research Organization (CRO) and a clinical technology solution provider. Mitch contracted 12 of the first 16 partners leading up to Medidata’s 2009 IPO, then left the field to lead global Field Enablement.
Since then, he has continued to innovate at the intersection of CROs and clinical technology, successfully commercializing partner models for three additional solution providers in 2019, 2021, and 2022.
Mitch is the founder of Arlen Consulting Group LLC (ACG), a consultancy focused on building high-impact partnerships between clinical technology providers and CROs. ACG helps CROs create tech-enabled competitive advantage and differentiation to drive higher win rates and increased sponsor stickiness.
ACG is curating a portfolio of innovative technology solutions designed to address critical pain points across clinical development, enabling CROs and other non-sponsor organizations to differentiate, deepen and expand sponsor relationships.
For startups and emerging clinical solution providers, ACG also offers targeted expertise in CRO value positioning, go-to-market readiness, and tailored strategies for business development and commercial field execution.
Introduction to Court Square Group and Podcast
- Keith Parent introduces himself as the CEO of Court Square Group and explains the purpose of the podcast.
- Court Square Group manages infrastructure for life science companies and has a content repository called RegDocs365™.
- Keith highlights the diverse customer base, including consulting firms, sponsor companies, CROs, CDMOs, and global laboratories.
- Keith introduces Mitchell Bayer, the managing partner of Arlen Consulting Group, and expresses his interest in Mitchell’s background.
Mitchell Bayer’s Career Journey
- Mitch shares his 24+ years of experience in the industry, starting with Medidata as a startup in 2002.
- He describes his early roles at Medidata, including marketing, sales, HR, and various functions for the founders.
- Mitch discusses the creation of the CRO partner program, ASPire to Win™ in 2005, which enabled CROs to leverage Medidata’s product, Rave.
- The program helped Medidata go public in 2009 and was a significant part of their growth and success.
Challenges and Successes with Early CROs
- Keith and Mitch discuss the transition from paper-based drug development to electronic data capture (EDC) systems.
- Mitch explains the early challenges of competing against paper-based trials and the importance of beta partners like ICON.
- He highlights the commitment and integrity of Medidata in training and supporting CROs, even when competing against other EDC companies.
- Mitch emphasizes the importance of being a good partner and offering support to all CROs, not just formal partners.
Evolution of the Life Science Industry
- Keith and Mitch discuss the evolution of the life science industry, focusing on the shift from big pharma to biotech and med device companies.
- Mitchell shares his experience with small CROs like PharmalinkFHI, which had only run electronic trials, and the importance of training and supporting them.
- They discuss the trend of CROs acquiring small companies to incorporate their tools and create their own revenue streams.
- Mitch highlights the importance of persistence and understanding the value proposition when working with CROs of all sizes.
Technology and Innovation in CROs
- Mitch explains his approach to identifying and representing technologies that can make CROs more competitive.
- He emphasizes the importance of selling direct and solving real problems for CROs.
- Mitch shares an example of a client, Slope Clinical, which has an amazing biospecimen management platform that digitizes the entire journey of a bio specimen.
- He discusses the importance of integration and ease of use for technologies that are adopted by CROs and clinical sites.
Future of AI and Technology in CROs
- Mitch discusses the future of AI and its impact on CROs, emphasizing the need for CROs to leverage AI for competitive advantage.
- He reflects on the prediction made by Glen de Vries in 2002 that there would be no EDC in 25 years, and how the industry has evolved.
- Mitchell believes that the future will see a blending of healthcare and research, with AI playing a significant role in clinical data management.
- Keith and Mitchell discuss the potential for AI to transform clinical operations and regulatory information management.
Conclusion and Final Thoughts
- Keith thanks Mitch for his insights and contributions to the podcast.
- Mitch encourages listeners to reach out to him if they have technologies that can help CROs and offers to help socialize these technologies with CROs.
- They discuss the importance of collaboration and bringing together a group of experts to solve complex problems in the industry.
We are usually asked about
What is a CRO technology partner program?
CRO technology partner program is a formal alliance between a Contract Research Organization and a clinical technology provider that enables the CRO to deploy, support, and sell a technology solution as part of its service offering. These programs typically include training, enablement resources, and co-selling support. When structured effectively, they allow CROs to differentiate their capabilities, improve trial efficiency, and strengthen sponsor relationships.
How do technology partnerships give CROs a competitive advantage?
CROs that integrate purpose-built clinical technologies — such as electronic data capture (EDC), biospecimen management, or AI-driven trial tools — can deliver faster timelines, reduced site burden, and more seamless sponsor experiences than competitors relying on manual or fragmented systems. Technology partnerships allow CROs to expand their service value without building proprietary tools from scratch. The result is higher win rates, deeper sponsor stickiness, and measurable operational differentiation.
What role does AI play in the future of clinical trials for CROs?
AI is increasingly being used in clinical trials to automate data management, accelerate regulatory workflows, and reduce administrative burden on clinical sites. For CROs, AI-powered tools offer an opportunity to improve trial speed, data accuracy, and resource efficiency at scale. Industry experts anticipate that AI will blur the lines between healthcare delivery and clinical research, creating new models for how trials are designed, executed, and monitored.
What is electronic data capture (EDC) and why does it matter for clinical trials?
Electronic data capture (EDC) is a digital system used to collect, manage, and store clinical trial data, replacing paper-based processes. EDC systems improve data quality, accelerate trial timelines, and enable real-time monitoring by sponsors and CROs. The shift from paper to EDC was a foundational transformation in clinical research, and it paved the way for today’s more advanced clinical technology ecosystems.
How can emerging clinical technology companies successfully partner with CROs?
Emerging clinical technology providers looking to partner with CROs should focus on clearly articulating how their solution reduces site burden, integrates with existing systems, and solves a specific operational pain point. Demonstrating go-to-market readiness, CRO value positioning, and a scalable enablement model are critical to earning CRO buy-in. Working with experienced consultants who understand both the technology and CRO business models can significantly accelerate time-to-partnership.